Fredag 14 Mars | 13:03:46 Europe / Stockholm
2025-03-04 09:40:19

Lipum has successfully completed its phase I clinical study with positive results. The study confirms that the drug candidate SOL-116 is safe, exhibits the expected pharmacokinetics, and effectively inhibits the target protein BSSL in both healthy volunteers and patients with rheumatoid arthritis. Additionally, the findings suggest that a once-monthly administration is an optimal dosing regimen. The company's CMO, Peter Hovstadius, discusses the results in an interview.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/03/lipum-successfully-completes-study-cmo-looks-ahead-to-the-next-chapter/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se